May 10, 2022 Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors
April 27, 2022 Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma
April 13, 2022 Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal
April 8, 2022 Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR
March 23, 2022 Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma
March 10, 2022 Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
January 11, 2022 Neogene Therapeutics Announces Exclusive License with the National Cancer Institute for a Portfolio of T Cell Receptors (TCR) Targeting KRAS and TP53 Mutations for the Treatment of Cancer
January 11, 2022 Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
December 16, 2021 Neogene Therapeutics Appoints Raphaël Rousseau, M.D., Ph.D., as Chief Medical Officer
December 13, 2021 Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
December 13, 2021 Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
December 6, 2021 Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia
November 29, 2021 Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742
November 8, 2021 Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus’ Platform
September 30, 2021 Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021
September 20, 2021 Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board
August 12, 2021 Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)
August 2, 2021 Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors
July 27, 2021 Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)
June 30, 2021 Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma
June 4, 2021 Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology
May 26, 2021 Neogene Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA as Chief Operating Officer
